Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp239 | Anterior and Posterior Pituitary | ECE2019

Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature

Giuffrida Giuseppe , Ferrau Francesco , Laudicella Riccardo , Cotta Oana Ruxandra , Vento Antonio , Baldari Sergio , Cannavo Salvatore

Background: Pituitary tumours (PT) are generally benign, but they can rarely show an aggressive behaviour, invade surrounding structures and/or grow/recur despite multimodal treatment, making their management extremely challenging. According to the latest guidelines, temozolomide (TMZ) can be an option after failure of standard therapies in aggressive PT, while little data are available on alternative approaches such as peptide receptor radionuclide therapy (PRRT). Herein we r...

ea0049ep1443 | Thyroid (non-cancer) | ECE2017

The sensitivity and positive predictive value (PPV) of 131I-post-therapy whole body scan is higher than serum Tg values in detecting metastases in early stage of differentiated thyroid cancer patients

Campenni Alfredo , Pignata Salvatore Antonio , Siracusa Massimiliano , Vicchio Teresa Manuela , Trimarchi Francesco , Ruggeri Rosaria Maddalena , Baldari Sergio

The work-up of Differentiated Thyroid Cancer (DTC) patients includes thyroid surgery, thyroid remnant ablation (TRA) with 131-radioiodine and long life follow-up. 131I-post therapy whole body scan (pT-WBS) and thyroglobulin (Tg) are used in identifying metastatic patients. Some authors suggested to use post-surgical Tg (ps-Tg) values in deciding for or against TRA. The aim of our study was to verify the sensitivity and PPV of 131I-pT-WBS compared to serum Tg levels in detectin...

ea0060oc2 | (1) | UKINETS2018

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

Prasad Vikas , Srirajaskanthan Raj , Toumpanakis Christos , Grana Chiara Maria , Baldari Sergio , Shah Tahir , Lamarca Angela , Courbon Frederic , Scheidhauer Klemens , Baudin Eric , Thanh Xuan Mai Truong , Houchard Aude , Bodei Lisa

Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogues such as lanreotide autogel (LAN). PRELUDE is the first international, multicentre retrospective study, with central radiology reading, to describe use of LAN with PRRT (LAN-PRRT) in advanced NETs.Methods: PRELUDE (NCT02788578) was an international, retrospective, non-comparative analysis of medical records of patients receiving LAN with 177Lu-DOTAT...

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...